Loading stock data…
$4.70-0.02 (-0.53%)
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
Nuvation Bio Inc. in the Healthcare sector is trading at $4.70 with a market capitalization of $2.4B. Wall Street consensus targets $13.00 (11 analysts), implying a +176.9% move over the next 12 months. The stock is currently 52% below its 52-week high of $9.75, remaining 16.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. Risk note: RSI 12 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $31.69M↓ | $83.23M↑ | $41.87M↑ | $13.12M↑ | $4.83M |
| Gross Profit | $22.22M↓ | $77.24M↑ | $40.59M↑ | $9.77M↑ | $2.26M |
| Operating Income | -$51.04M↓ | $3.88M↑ | -$34.04M↑ | -$56.43M↑ | -$63.59M |
| Net Income | -$62.84M↓ | $5.40M↑ | -$36.59M↑ | -$55.79M↑ | -$59.01M |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ n...